California Signs PBM Law: As Federal PBM Regulation Lags, the States Step Up
With federal PBM reform stalled, states like California are stepping up with laws like SB 41 to boost transparency and lower drug costs.
presented by
Northern California Mental Health Services for Veterans: Cost-Effective Solutions
Transitioning from military to civilian life can be overwhelming, especially for veterans facing mental health challenges, such as post-traumatic stress disorder (PTSD), depression or substance use disorders. The most affordable mental health treatment programs for veterans in Northern California offer affordable and specialized care tailored to veterans across the state.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
California’s Top Revision Facelift Surgeons: Achieving Optimal Results
California’s leading facial plastic surgeons redefine revision facelifts through precision, innovation and patient-centered artistry. Find out which ones get the best results.
Policy Innovation Is Outpacing Technology at the Intersection of Health Care and Human Services
Profound opportunities and challenges are playing out at the intersection of the two.
23andMe: What If …
A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?
Carmot’s IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes Targets
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
NEMT Partner Guide: Why Payers and Providers Should Choose MediDrive’s TMS
Alan Murray on improving access for medical transportation.
Bayer’s New $250M Cell & Gene Therapy Site Signals More Investments to Come
Bayer opens its new cell therapy manufacturing facility as it prepares a Parkinson’s disease cell therapy for Phase 2 testing. The new 100,000 square foot facility also has space for manufacturing other cell therapies in the pharma giant’s pipeline.
Neuro Startup Arialys Raises $58M for Privilege of Tackling Brain Inflammation
Avalon BioVentures unveiled new portfolio company Arialys Therapeutics. The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder.
Amgen, FTC Settlement Allows $28B Horizon Acquisition to Move Forward
Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
43K Patients in California Could Get Refunds, Bill Corrections As Part of Discounted Care Settlement
Santa Clara Valley Healthcare in California has begun notifying 43,000 patients about their eligibility for billing corrections and refunds. The system’s patient outreach effort is a result of a recently settled lawsuit filed against Santa Clara County. In the complaint, former patients alleged the county did not inform them about its hospitals' charity care and discount payment policies, leading them to have to pay large bills.
presented by
5 High-Impact Tax Strategies Every Physician Should Use in 2026 to Reduce Their Tax Bill
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
Novartis Pays Ionis $60M to Expand Alliance on a Hot Target for Cardio Drugs
Novartis and Ionis Pharmaceuticals, already partners in cardiovascular disease R&D, are expanding their alliance to see if they can develop a next-generation therapy offering efficacy and dosing advantages. But competitors are already in the mix with programs addressing the same cardiovascular disease target.
Startup Fundraising Spotlight: Octave Bioscience
Octave Bioscience, based in Menlo Park, California, just closed a $30 million extension to its Series B funding round.
Turnstone Bio Goes IPO to Fund Clinical Tests of New Kind of Cancer Cell Therapy
Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.
FDA Approves BioMarin Pharma’s Gene Therapy, the First for Hemophilia A
The FDA approved Roctavian for treating hemophilia A. The regulatory decision makes the BioMarin Pharmaceutical product the first gene therapy for this inherited bleeding disorder.
How California’s New Legislation Could Affect Healthcare M&A Activity
Healthcare dealmakers must prepare for a new law and a recently-introduced bill in the California Senate, both of which aim to increase oversight in the healthcare M&A space. This is a legislative trend other states are beginning to participate in too — such as New York, Massachusetts and Connecticut.